Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24752018 | 1.00 | ALDH1A1 (0.38) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL30138039 | 0.85 | ALDH1A1 (0.35) | ALDH1A1KMT2A | |
| SCHEMBL24752660 | 0.85 | ALDH1A1 (0.35) | ALDH1A1KMT2A | |
| SCHEMBL30853071 | 0.84 | ALDH1A1 (0.32) | ALDH1A1KMT2A | |
| SCHEMBL24752020 | 0.84 | ALDH1A1 (0.32) | ALDH1A1KMT2A | |
| SCHEMBL30138073 | 0.84 | ALDH1A1 (0.32) | ALDH1A1KMT2A | |
| SCHEMBL30137942 | 0.84 | ALDH1A1 (0.32) | ALDH1A1KMT2A | |
| SCHEMBL1976614 | 0.82 | KMT2A (0.36) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL24752670 | 0.71 | ALDH1A1 (0.35) | ALDH1A1KMT2A | |
| SCHEMBL30067139 | 0.71 | ALDH1A1 (0.35) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4355748-B1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2026-05-13 | — | — | EP | disclosed |
| US-20240383901-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2024-11-21 | — | — | US | disclosed |
| EP-4355748-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2024-04-24 | — | — | EP | disclosed |
| WO-2022263472-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2022-12-22 | — | — | WO | disclosed |
| EP-4105218-A1 | SUBSTITUTED PYRROLO[2,3-D] PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2022-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383901-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | LRRK2, PARK7, SNCA | ALDH1A1 1457/4885KMT2A 1848/4885MEN1 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.